Feb 16, 2021
Sosei Heptares spin-off company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals
Feb 12, 2021
Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020
Feb 01, 2021
Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences
Jan 12, 2021
Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target
Jan 11, 2021
Sosei Heptares to present at 39th Annual J.P. Morgan Healthcare Conference
Jan 05, 2021
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
Dec 22, 2020
Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
Dec 20, 2020
Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System
Dec 01, 2020
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
Nov 11, 2020
Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months ended 30 September 2020
Nov 02, 2020
Sosei Heptares and Aditum Bio create new company - Tempero Bio - to advance the clinical development of mGlu5 NAM program in neurological diseases
Sep 28, 2020
Sosei Heptares announces that a second novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
Sep 03, 2020
Sosei Heptares Appoints Top-Ranked Investment Analyst Hironoshin Nomura as Senior Vice President, Investor Relations and Corporate Strategy
Aug 13, 2020
Sosei Heptares Operational Highlights and Consolidated Results for the First Half 2020
Jul 16, 2020
Sosei Heptares Successfully Raises US$200 million in International Offering of New Shares and Convertible Bonds
Jun 05, 2020
Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma
May 13, 2020
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2020
May 07, 2020
Sosei Heptares Announces Further Scientific Progress with Orexin Agonist Program in Conjunction With Spin-off Companies Orexia and Inexia
May 01, 2020
Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma
Apr 14, 2020
Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program